title: [Tyrosine kinase inhibitors and pregnancy: A risk to the fetus?].
abstract: The association of cancer and pregnancy is increasingly frequent. This is related, partially, to the increasingly belated age of pregnancy. The management of cancer in pregnancy is a complicated issue. The use of tyrosine kinase inhibitors (TKIs) during pregnancy remains rare and only few data are available concerning their transplacental passage. The aim of this work is to review the data described in the literature, in order to highlight the risks incurred by the fetus, associated with these TKIs' treatment. Up to 189 pregnancies of women treated with TKIs during part or throughout their pregnancy have been described. Clinical data are reassuring and would be in favor of taking the treatment in terms of the balance maternal profit versus fetal risk. These data must, nevertheless, be interpreted with caution.
authors.affiliation: Gustave-Roussy, laboratoire de recherche translationnelle, 114, rue Edouard-Vaillant, 94805 Villejuif, France.
authors.forename: Cécile
authors.initials: C
authors.lastname: Jovelet
authors.affiliation: Gustave-Roussy, service de pharmacologie et d'analyse du médicament, 114, rue Edouard-Vaillant, 94805 Villejuif cedex, France.
authors.forename: Sophie
authors.initials: S
authors.lastname: Broutin
authors.affiliation: Université Paris Descartes, Inserm, UMR-S 1139, 4, avenue de l'Observatoire, 75006 Paris, France.
authors.forename: Sophie
authors.initials: S
authors.lastname: Gil
authors.affiliation: Université Paris Sud, Gustave-Roussy, département de médecine oncologique, 114, rue Edouard-Vaillant, 94805 Villejuif, France.
authors.forename: Olivier
authors.initials: O
authors.lastname: Mir
authors.affiliation: Gustave-Roussy, service de pharmacologie et d'analyse du médicament, 114, rue Edouard-Vaillant, 94805 Villejuif cedex, France. Electronic address: angelo.paci@gustaveroussy.fr.
authors.forename: Angelo
authors.initials: A
authors.lastname: Paci
mesh_terms: D000014:Abnormalities, Drug-Induced; D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000493:pharmacokinetics; D000069439:Dasatinib / Q000009:adverse effects; D000069347:Erlotinib Hydrochloride / Q000009:adverse effects; D005260:Female; D005333:Fetus / Q000187:drug effects*; D000077156:Gefitinib; D006801:Humans; D000068877:Imatinib Mesylate / Q000009:adverse effects / Q000493:pharmacokinetics; D000077341:Lapatinib; D008423:Maternal Age; D010920:Placenta / Q000378:metabolism; D011247:Pregnancy; D011252:Pregnancy Complications, Neoplastic / Q000188:drug therapy* / Q000378:metabolism; D047428:Protein Kinase Inhibitors / Q000009:adverse effects* / Q000493:pharmacokinetics; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors* / Q000493:pharmacokinetics; D011743:Pyrimidines / Q000009:adverse effects; D011799:Quinazolines / Q000009:adverse effects; D012306:Risk
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D011799:Quinazolines; D000077341:Lapatinib; D000068877:Imatinib Mesylate; D000069347:Erlotinib Hydrochloride; D011505:Protein-Tyrosine Kinases; C498826:nilotinib; D000069439:Dasatinib; D000077156:Gefitinib
keywords: Cancer; Grossesse; Inhibiteurs de tyrosine kinase; Pregnancy; Tyrosine kinase inhibitors